Mr. Berg joined Amarin in November 2012 and has over 25 years of life science industry experience. Mr. Berg was initially positioned at Amarin as Vice President, Marketing and Managed Care. He was promoted to Senior Vice President, Marketing and Sales in February 2014, and to the position of Senior Vice President and Chief Commercial Officer in April 2018, then Executive Vice President, President U.S., in August 2021. He briefly served as Interim President and CEO in April 2023 before returning to his position of EVP, President U.S., in July 2023. Mr. Berg was appointed President and Chief Executive Officer in June 2024.

Mr. Boothe joined Amarin in January 2012 and has more than 20 years of experience in executive commercial leadership, market access, marketing and business development in the biopharmaceutical industry, including roles at Alpharma and Reliant Pharmaceuticals. Prior to his current role as Senior Vice President, Corporate Development, Mr. Boothe spent time leading Business Development and Alliance Management as well as the US Sales and Marketing organization.

Mr. Fishman joined Amarin in January 2019 and has nearly 20 years of experience in various finance areas and leading global finance teams. Mr. Fishman most recently served as the Company’s principal financial and accounting officer since October 2024, and as Vice President & Global Controller since October 2022. Previously, he held roles of increasing responsibility within Amarin’s Finance team since 2019. Mr. Fishman has been involved in numerous complex transactions while with the Company as well as played an integral part in the Company’s current cash management strategy.

Dr. Keenan joined Amarin in May 2022 as Senior Vice President of Technical Operations. He now serves as Executive Vice President and Chief Operating Officer, overseeing technical operations, alliance management, and information technology. With over 30 years of leadership experience in the biopharmaceutical and medical device sectors, Dr. Keenan offers extensive expertise in quality management, technical operations, commercial leadership, global M&A and integration, change management, and greenfield site launches.

Dr. Ketchum joined Amarin in February 2012 as President of Research and Development. He brings over 20 years of experience in late-stage product development and clinical regulatory strategy, having led the filings of multiple successful new drug applications (NDAs) and supplemental NDAs.

Mr. Provoost joined Amarin in November 2023 and has more than 20 years of experience in corporate counsel and compliance with medium and large-sized pharmaceutical companies. Mr. Provoost most recently served as Vice President, General Counsel and Chief Compliance Officer at Tris Pharma. Earlier in his career, Mr. Provoost served in roles of increasing responsibility at Mallinckrodt Pharmaceuticals, Ikaria, Kos Pharmaceuticals and Bristol-Myers Squibb.